TRVI
NASDAQTrevi Therapeutics Inc.
Website
News25/Ratings12
Price$14.18+3.76 (+36.08%)
2026-01-202026-04-23
News · 26 weeks49+57%
2025-10-262026-04-19
Mix3490d
- Insider13(38%)
- SEC Filings9(26%)
- Other7(21%)
- Offering3(9%)
- Earnings2(6%)
Latest news
25 items- PRTrevi Therapeutics to Participate in Upcoming May EventsNEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May. Trevi Therapeutics Investor and Analyst DayMay 7, 2026, Midtown New York, New York10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussionsRepresentatives: Trevi senior management will be joined by key opinion leaders
- SECSEC Form DEF 14A filed by Trevi Therapeutics Inc.DEF 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECSEC Form DEFA14A filed by Trevi Therapeutics Inc.DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesNEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of
- SECSEC Form 424B5 filed by Trevi Therapeutics Inc.424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of t
- SECSEC Form 424B5 filed by Trevi Therapeutics Inc.424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Announces Proposed Public Offering of Common StockNEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common
- SECSEC Form PRE 14A filed by Trevi Therapeutics Inc.PRE 14A - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics to Participate in Upcoming EventsNEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events. 25th Annual Needham Virtual Healthcare ConferenceApril 13 – 16, 2026, Virtual Fireside Chat: April 13, 12:45 p.m. ET Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFORaymond James 2026 Biotech Innovatio
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Trevi Therapeutics Inc.SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
- SECSEC Form 10-K filed by Trevi Therapeutics Inc.10-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdatesFollowing the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
- PRTrevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. Conference Call and WebcastTo register for the live co
- SECTrevi Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
- PRTrevi Therapeutics to Participate in Upcoming March ConferencesNEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare ConferenceMarch 8 – 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister h
- INSIDERSEC Form 4 filed by Chief Development Officer Cassella James V4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Officer Galletta Christopher4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Sciascia Thomas4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Good Jennifer L4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Simon Farrell4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
- PRTrevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceNEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, at 9:20 a.m. ET. Held virtually from February 25-26, Ms. Good and Mr.
- INSIDERSEC Form 5 filed by Sandell Scott D5 - Trevi Therapeutics, Inc. (0001563880) (Issuer)